HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
BIOBOARD - INSIDE INDUSTRY
Biolife Science $5m ASX listing to progress stomach & breast cancer vaccine
Australian shareholders are being given the opportunity to buy into a highly promising biotech with a vaccine that shows significant potential in the fight against stomach (gastric) and breast cancer.

Biolife Science Limited will be acquired by Perth-based Acuvax Limited. The Patersons-managed raising aims to generate up to $5 million for Phase II clinical trials of Biolife’s HER-Vaxx vaccine, which has shown significant success in stimulating the production of lifesaving HER-2 antibodies in late-stage cancer patients.

HER-Vaxx is expected to provide a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which has become one of the world’s best-selling cancer drugs with sales of $US6.4 billion in 2012. Metastatic breast cancer patients in Biolife’s Phase I study developed HER-2 antibodies that produced potent anti-tumour activity, thus inducing an antibody response with similar anti-tumour properties to Roche’s Herceptin® and effectively turning the patient’s body into a “Herceptin® factory”.

An Investigational New Drug (IND) application is expected to be filed with the FDA Q3, 2013 and Biolife has already appointed a leading Swiss vaccine producer Pevion Biotech AG to manufacture the HER-Vaxx vaccine. This will be ready for the commencement of the subsequent Phase II clinical study.

The incoming management team includes seasoned biotechnology executives and company builders Dr. Roger Aston and Mr Paul Hopper as well as a Scientific Advisory Board that includes several of the inventors.

Dr. Aston has held leadership roles with ASX listed companies Peptech, Cambridge Antibody, Clinuvel, pSivida and Mayne Pharma. Mr Hopper is Head of the Life Sciences Desk of US investment bank Cappello Capital Corp and is a director of ASX listed Viralytics and pSivida. Both have extensive experience developing vaccines, undertaking clinical trials and marketing products.

Director elect, Dr. Axel Hoos, will also be joining the Board. Dr. Hoos is Vice President, Oncology R&D with GlaxoSmithKline and brings a wealth of experience in cancer drug development to Biolife.

“This is an exhilarating moment for Biolife, which can now see a new life for itself and for one of the most promising new oncology drugs to emerge in recent times,” Dr. Aston said. “We have no doubt that this represents the most expedient way forward for our shareholders, our technology, and – ultimately – for the thousands of cancer patients that stand to benefit from this highly promising vaccine.”

“Given the comparatively low levels of investment activity in Europe, the opportunity has arisen to progress this ground-breaking vaccine with Australian funds for clinical studies in Europe and possibly also in Australia.”

After undergoing a 200 to 1 share consolidation, Acuvax is seeking to raise up to $5 million through the placement of up to 25 million shares at $0.20 each – giving Biolife an initial market cap of $11.3 million and paving the way for the Phase II trials of HER-Vaxx following approval of an FDA IND application.

Stomach cancer and breast cancer are among the most virulent forms of cancer, killing more than 1.2 million people globally each year. The market for stomach cancer drugs alone is projected to rise to nearly $1.4 billion by 2020 – with nearly 20% of patients suffering from HER-2 positive forms of the disease. Between 25-30% of breast cancers are HER-2 positive.

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy